Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
78 participants
OBSERVATIONAL
2011-10-30
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Diabetic retinopathy is an eye disease associated with diabetes in which the cells of the retina are damaged. It can cause blurred vision, vision loss, blindness or possible bleeding in the retina. Even with current treatments, the quality of life for people with diabetic retinopathy is much reduced.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diabetic Patients
Mild, Moderate and Severe Retinopathy
Diabetic Patients
measuring CD34 cell function in relation to diabetic retinopathy status
Healthy Controls
Age and sex matched Healthy Controls
Healthy Controls
measuring CD34 cell function
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diabetic Patients
measuring CD34 cell function in relation to diabetic retinopathy status
Healthy Controls
measuring CD34 cell function
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 39 type 1 or type 2 diabetic patients
* 13 with mild retinopathy
* 13 with moderate retinopathy
* 13 with severe, nonproliferative retinopathy
* 39 age and sex matched healthy controls
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
University of Alabama at Birmingham
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Maria Grant
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maria B Grant, MD
Role: PRINCIPAL_INVESTIGATOR
University of Alabama at Birmingham
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama
Birmingham, Alabama, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1308798827
Identifier Type: -
Identifier Source: org_study_id